Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2022 Feb 9, 2022
Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference Feb 3, 2022
Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN) Dec 9, 2021
Aurinia Announces Updated Interim Results from the AURORA 2 Continuation Study of LUPKYNIS (voclosporin) for the Treatment of Lupus Nephritis Nov 1, 2021
Aurinia Pharmaceuticals to Release Third Quarter 2021 Financial Results on November 3, 2021 Oct 27, 2021
